For research and educational purposes only. Not intended for human consumption.
Thymosin Beta-4
Well Researched- •Tissue regeneration mechanisms confirmed
- •Cardiac repair applications studied
- •Stem cell recruitment pathways detailed
43-Amino Acid Regenerative Peptide | Tissue Repair & Healing
Overview
What is Thymosin Beta-4?
Thymosin Beta-4 (Tβ4) is a naturally occurring 43-amino acid peptide that plays a crucial role in tissue repair, wound healing, and cellular regeneration. It promotes angiogenesis, reduces inflammation, and supports the migration and differentiation of various cell types involved in healing processes. Banned by WADA
Key Benefits
Systemic regenerative effects, proven clinical efficacy, optimal bioavailability for tissue repair.
Mechanism of Action
Direct systemic delivery provides optimal bioavailability and distribution to target tissues for comprehensive regenerative effects. Promotes actin sequestration, angiogenesis, and stem cell recruitment.
Molecular Information
Pharmacokinetics
Research Indications
Wound Healing Acceleration
Clinical trials show 67% complete healing vs 25% placebo in pressure ulcers.
Post-Surgical Recovery
Enhanced tissue regeneration and reduced healing time in surgical wounds.
Soft Tissue Injury Repair
Accelerated recovery in muscle, tendon, and ligament injuries.
Research Protocols
Disclaimer: Thymosin Beta-4 is the full-length parent peptide of TB-500. These protocols are based on clinical research. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Acute Wound Healing | 1.6mg | Daily | Subcutaneous injection |
| Cardiac Protection | 42mg | Single dose | IV bolus within 6 hours of MI |
| Chronic Tissue Repair | 6mg | Twice weekly | Subcutaneous injection |
| Neurological Recovery | 30mg | Three times over 72 hours | IV infusion |
| General Regeneration | 2-5mg | Daily or every other day | Subcutaneous injection |
Timing: Most effective when started early in the injury/healing process. For cardiac protection, must be given within 6 hours of symptom onset.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Allow lyophilized powder to reach room temperature before reconstitution
Add bacteriostatic water slowly to the vial wall, avoiding direct contact with powder
Gently swirl (do not shake vigorously) until completely dissolved
Inspect solution for clarity - should be clear and colorless
Store reconstituted solution at 2-8°C and use within 14 days
For injection, use proper aseptic technique and rotate injection sites
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
Clear, colorless solution
Reconstituted Thymosin β4 should be clear without particles.
Proper sterile packaging
Lyophilized powder in sterile vials with intact seals.
Certificate of analysis
Third-party testing showing >98% purity.
Appropriate molecular weight
HPLC/MS confirmation of 4,963 Da.
Cloudy or discolored solution
Indicates degradation or contamination.
Crystallization after reconstitution
Suggests improper storage or expired product.
What to Expect
- •Week 1-2: Initial tissue response, possible mild injection site reactions
- •Week 2-4: Accelerated healing becomes apparent, reduced inflammation
- •Week 4-8: Significant tissue regeneration and functional improvement
- •Week 8-12: Sustained benefits and near-complete healing in responsive conditions
Side Effects & Safety
Side Effects
- •Monitor injection sites for local reactions or inflammation
- •Use sterile technique to prevent infection at injection sites
- •Start with lower doses to assess individual tolerance
- •Discontinue if signs of allergic reaction or unusual side effects
When to Stop
- •Signs of allergic reaction
- •Severe injection site reactions
- •Unexpected symptoms
- •As directed by healthcare provider
References
3 StudiesCardiac Protection Pilot Study (2016)
Human | EPC pre-treatment with Tβ4 | Single transplantation | Improved cardiac function
First human study demonstrating potential clinical benefits in repairing damaged cardiac tissue.
Phase II Dry Eye Clinical Trial (2015)
Human | 0.1% topical drops | 28 days | Significant symptom improvement
Randomized study in 72 subjects showing significant positive effects on ocular discomfort.
Phase I Human Safety Study (2010)
Human | 42-1260 mg IV | Single and multiple doses | Excellent safety profile
First-in-human study establishing safety and pharmacokinetics of IV Thymosin β4.
Quick Start Guide
Research Disclaimer
Thymosin Beta-4 is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving Thymosin Beta-4 must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of Thymosin Beta-4 for any purpose. Consult qualified professionals for any research applications.